| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0795159560729f14b8770c670f347322 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-22 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2021-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c7fd9ee96f2671f61f7142437b75459
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4903ee26e39c5c93c1211ad8355791b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24b48de733d26324d7e9c9103d90d78c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f18bb0fd3a3ae2d23878009475b15f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1855a47cea0f17d49b7a4cf36fa03274
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e1b4b2ece6ad7da69bf21b726825a3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba7478d17926b47971d1ef91763fe95f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e69dcc52454fe625d35f0f260f466220
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aab3e5dda299ca8ec53b0447ce0c1a05 |
| publicationDate |
2022-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022006451-A2 |
| titleOfInvention |
Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies |
| abstract |
The present disclosure provides T-cell (receptor) fusion proteins (TFPs) comprising binding domains targeting various antigens associated with a disease or nucleic acid molecules encoding such TFPs. The present disclosure also provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids molecules encoding the anti-PD-1 antigen-binding proteins. The present disclosure further provides modified T cells expressing such TFPs or antigen-binding protein or fragment thereof, and methods of regulating T cells or treating patients using such constructs or modified T cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022192439-A1 |
| priorityDate |
2020-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |